ORKA
NASDAQOruka Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
$68.97+1.37 (+2.03%)
News25/Ratings11
Price$68.97+1.16 (+1.71%)
01:30 PM07:45 PM
News · 26 weeks42-50%
2025-11-022026-04-26
Mix1990d
- Insider8(42%)
- SEC Filings6(32%)
- Other5(26%)
Latest news
25 items- SECSEC Form 424B7 filed by Oruka Therapeutics Inc.424B7 - Oruka Therapeutics, Inc. (0000907654) (Filer)
- SECSEC Form DEFA14A filed by Oruka Therapeutics Inc.DEFA14A - Oruka Therapeutics, Inc. (0000907654) (Filer)
- SECSEC Form DEF 14A filed by Oruka Therapeutics Inc.DEF 14A - Oruka Therapeutics, Inc. (0000907654) (Filer)
- INSIDERSEC Form 4 filed by Goncalves Joana4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- SECSEC Form EFFECT filed by Oruka Therapeutics Inc.EFFECT - Oruka Therapeutics, Inc. (0000907654) (Filer)
- SECSEC Form S-3 filed by Oruka Therapeutics Inc.S-3 - Oruka Therapeutics, Inc. (0000907654) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Oruka Therapeutics Inc.SCHEDULE 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)
- INSIDERChief Executive Officer Klein Lawrence Otto sold $71,408 worth of shares (1,729 units at $41.30), decreasing direct ownership by 0.19% to 927,309 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSenior Vice President, Finance Agarwal Arjun sold $16,313 worth of shares (395 units at $41.30), decreasing direct ownership by 2% to 18,863 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Operating Officer Sandler Laura Lee sold $24,780 worth of shares (600 units at $41.30), decreasing direct ownership by 0.25% to 236,984 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $312,560 worth of shares (7,641 units at $40.91), decreasing direct ownership by 2% to 33,377 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERGeneral Counsel Quinlan Paul T sold $30,273 worth of shares (733 units at $41.30), decreasing direct ownership by 2% to 31,767 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- SECSEC Form S-8 filed by Oruka Therapeutics Inc.S-8 - Oruka Therapeutics, Inc. (0000907654) (Filer)
- PROruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected 2027 $479.6 million in cash, cash equivalents and marketable securities MENLO PARK, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today reported fourth quarter and full year 2025 financial results and provided a corporate update. "We are very pleased with
- SECSEC Form 10-K filed by Oruka Therapeutics Inc.10-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
- INSIDERChief Operating Officer Sandler Laura Lee sold $167,822 worth of shares (5,000 units at $33.56) and exercised 5,000 shares at a strike of $7.80 (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $226,559 worth of shares (7,000 units at $32.37) (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- PROruka Therapeutics to Participate in Multiple Upcoming ConferencesMENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its participation and presentation at multiple upcoming conferences: Guggenheim Emerging Outlook: Biotech Summit 2026Date: Thursday, February 12th, 2026Presentation Time: 10:30AM ET TD Cowen 46th Annual Health Care ConferenceDate: Tuesday, March 3rd, 2026Presentation Time: 1:10PM ET UBS Biotech Summit MiamiDate: Monday March 9th, 2026 Jefferies Biotech on the Beach SummitDate: March 10th, 2026 Leerink
- SECSEC Form SCHEDULE 13G filed by Oruka Therapeutics Inc.SCHEDULE 13G - Oruka Therapeutics, Inc. (0000907654) (Subject)
- INSIDERChief Medical Officer Goncalves Joana was granted 32,500 shares, increasing direct ownership by 2,141% to 34,018 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Operating Officer Sandler Laura Lee was granted 32,500 shares, increasing direct ownership by 16% to 237,584 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSVP, Finance Agarwal Arjun was granted 17,500 shares, increasing direct ownership by 995% to 19,258 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Executive Officer Klein Lawrence Otto was granted 76,700 shares, increasing direct ownership by 9% to 929,038 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERGeneral Counsel Quinlan Paul T was granted 32,500 shares (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERDirector Dambkowski Carl acquired 116,483 shares (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)